Physician profile
Gilbert E Daniel
NPI 1467401182
$7,404.44
in general payments reported to CMS, 2019-2025
38 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $286 · 2021: $198 · 2022: $757 · 2023: $1,885 · 2024: $2,068 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,128.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,105.96 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $894.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $616.26 | 2019-2024 | |
| Alkermes, INC. | $349.49 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $344.04 | 2022-2025 | Vraylar |
| Gilead Sciences, INC. | $320.75 | 2022-2025 | Biktarvy |
| Amgen INC. | $315.71 | 2023-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.36 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $304.65 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $302.87 | 2023-2024 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $299.08 | 2023-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $269.94 | 2023-2024 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $232.78 | 2023-2024 | Austedo Xr, Austedo |
| Abbott Laboratories | $225.48 | 2022-2023 | Freestyle Libre 3 |
| Pfizer INC. | $179.62 | 2019-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $152.43 | 2023-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $151.19 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Janssen Biotech, INC. | $132.75 | 2022-2023 | Symtuza |
| Neurocrine Biosciences, INC. | $100.53 | 2022-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $90.47 | 2023-2024 | Hetlioz, Fanapt |
| Merck Sharp & Dohme LLC | $89.69 | 2023-2025 | Verquvo |
| Lundbeck LLC | $87.34 | 2024-2025 | Rexulti |
| Viiv Healthcare Company | $77.92 | 2024-2025 | Cabenuva, Dovato |
| E.R. Squibb & Sons, L.L.C. | $56.43 | 2024-2025 | Eliquis |
| Mylan Specialty L.P. | $52.85 | 2023-2024 | Yupelri |
| Neurelis, INC. | $42.23 | 2023 | Valtoco |
| Dexcom, INC. | $39.73 | 2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $37.10 | 2022-2023 | Minimed 780g |
| Allergan, INC. | $27.88 | 2019-2020 | |
| Supreme Orthopedic Systems, LLC | $27.55 | 2025 | |
| Zyla Life Sciences, INC. | $25.43 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.53 | 2022 | |
| Hologic Sales and Service, LLC | $22.43 | 2023 | Aptima |
| Sunovion Pharmaceuticals INC. | $22.00 | 2019 | |
| Phadia US INC. | $21.84 | 2025 | Immunocap |
| Eisai INC. | $19.43 | 2022 | |
| Hikma Pharmaceuticals USA | $13.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.